-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pharmacotherapy of peripheral T-cell lymphoma: review of the latest clinical data
Eric D Jacobsen
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation
-
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Deme John Karikios & Michael Joseph Boyer
Review: Clinical Trail Outcomes: Clinical Investigation